M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 7.35 PLN
Market Cap: 151.4m PLN

Molecure SA
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Molecure SA
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
M
Molecure SA
WSE:MOC
Stock-Based Compensation
zł4m
CAGR 3-Years
N/A
CAGR 5-Years
24%
CAGR 10-Years
N/A
C
Celon Pharma SA
WSE:CLN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Molecure SA
Glance View

Market Cap
151.4m PLN
Industry
Pharmaceuticals

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

MOC Intrinsic Value
4.43 PLN
Overvaluation 40%
Intrinsic Value
Price
M

See Also

What is Molecure SA's Stock-Based Compensation?
Stock-Based Compensation
4m PLN

Based on the financial report for Dec 31, 2024, Molecure SA's Stock-Based Compensation amounts to 4m PLN.

What is Molecure SA's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
24%

Back to Top